Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Hver dag tæller: Et livsstilsprogram for kvinder med metastaserende brystkræft (EDC)

2. oktober 2026 opdateret af: Melinda Stolley, Medical College of Wisconsin

This multi-site study is being conducted to examine dietary and activity patterns, body composition, blood and quality of life in breast cancer patients. The study will recruit 176 women with MBC in Milwaukee (n=88) and Chicago (n=88).

Studieoversigt

Status

Afsluttet

Betingelser

Intervention / Behandling

Detaljeret beskrivelse

Aims/Objectives

Aim 1. To examine the efficacy of the Every Day Counts intervention in producing significant post-intervention changes in multidimensional QOL in women with MBC.

Hypothesis 1: Women randomized to the immediate EDC intervention (n=88) will exhibit greater improvements in multidimensional QOL compared to women randomized to the attention control (n=88).

Aim 2. To investigate the mechanistic effects of the Every Day Counts intervention on body composition, adipokines, serum biomarkers of inflammation and insulin sensitivity.

Hypothesis 2: The EDC intervention leads to improved QOL through mediating factors including body composition, prognostic serum biomarkers of inflammation and/or insulin resistance.

Exploratory Aim 3: To explore if microRNA (miRNA) signatures associated with inflammation and/or Metabolomics are altered with the EDC intervention.

Hypothesis: miRNAs identified in our pilot study (miR-10a-5p, miR-205-5p, and miR-211-5p) that regulate inflammation and/or Metabolomics will be related to QOL improvements and can identify women more likely to respond to lifestyle changes.

Undersøgelsestype

Interventionel

Tilmelding (Faktiske)

180

Fase

  • Ikke anvendelig

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

  • Forenede Stater
    • Illinois
      • Maywood, Illinois, Forenede Stater, 60153
        • Loyola University
    • Wisconsin
      • Milwaukee, Wisconsin, Forenede Stater, 53226
        • Medical College of Wisconsin

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Kvinde

Beskrivelse

Inclusion Criteria:

  • Adult (≥ 18 years), female

  • Confirmed Metastatic Breast Cancer

  • Patients clinically stable with treated brain metastases are eligible

  • Written documentation from their oncologist permitting study participation

  • Determined to be "clinically stable" by their medical oncologist (i.e., no unintentional weight loss, no new symptoms or change in performance status for the past 4 weeks, no clinical [including laboratory] or radiologic evidence of disease progression, no recent or planned change in anti-neoplastic therapies, no reports of severe pain [≥ Grade 3 per the NCI CTCAE)

  • Life expectancy >6 months

    -Written documentation from their oncologist permitting study participation

  • Access to a mobile phone

  • Understand/speak English fluently.

  • Non-adherence to ACS nutritional or PA guidelines for cancer survivors as documented by questionnaire.

Exclusion Criteria:

  • Does not meet the above criteria.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Støttende pleje
  • Tildeling: Randomiseret
  • Interventionel model: Crossover opgave
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Immediate Intervention

The experimental arm will receive a 16-week lifestyle intervention that promotes nutritional and physical activity changes concordant with those contained in the ACS nutrition and physical activity guidelines for cancer survivors. The 16-week intervention includes:

1) a curriculum binder covering weekly topics and including self-monitoring tools to support adherence; 2) lifestyle coaching for 16-weeks, with in-person or virtual supervised exercise sessions and telephone-based sessions; 3) exercise supplies (Fitbit, resistance bands), 4) twice weekly text messaging targeting self-efficacy and social support; and 5) attendance to cooking classes emphasizing plant-based eating.
Adfærdsmæssigt: Lifestyle Intervention

The lifestyle intervention is a 16-week cognitive-behavioral intervention that addresses key changes in diet and PA behaviors to promote positive body composition changes.
Andet: Attention Control

The attention control participants will receive a home/work organization intervention:

  • Participants will receive a book with overview of home/work organization program with 16 weekly topics with an overview of each chapter.
  • Virtual or weekly phone calls- with a home organization coach with standard prompts.
  • Text messages supporting home/work organization.

Following completion of the attention control home/work organization program and 16-week assessment, women will receive the lifestyle program.
Adfærdsmæssigt: Attention Control

The attention control participants will receive a home/work organization intervention:

Following completion of the attention control home/work organization program and 16-week assessment, women will receive the lifestyle program.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Intervention adherence
Tidsramme: 4 months

Number of lifestyle coaching sessions completed out of a possible total of 16 sessions
4 months
Intervention retention
Tidsramme: 4 months

Number of women who complete the 4-month data collection
4 months
Intervention retention
Tidsramme: 8 months

Number of women who complete the 8-month data collection
8 months
Change in Quality of Life
Tidsramme: Change from baseline to 4 months

Patient reported outcomes as measured by Functional Assessment of Cancer Therapy-Measured by the Functional Assessment of Cancer Therapies Breast, Fatigue and Endocrine Symptoms (FACT-B, F and ES). The FACT-G is the overarching measure with a score range of 0-108; FACT-B (breast) subscale score range is 0-40; FACT-ES (endocrine symptoms) subscale score range is 0-76; FACT-F (fatigue) subscale is 0-52. Higher scores are better.
Change from baseline to 4 months
Change in Quality of Life
Tidsramme: change from baseline to 8 months

Patient reported outcomes as measured by Functional Assessment of Cancer Therapy-Measured by the Functional Assessment of Cancer Therapies Breast, Fatigue and Endocrine Symptoms (FACT-B, F and ES). The FACT-G is the overarching measure with a score range of 0-108; FACT-B (breast) subscale score range is 0-40; FACT-ES (endocrine symptoms) subscale score range is 0-76; FACT-F (fatigue) subscale is 0-52. Higher scores are better.
change from baseline to 8 months
Body composition
Tidsramme: change from baseline to 4 months

Ratio of percent lean mass to percent adiposity as measured by DEXA. More lean mass and less adiposity is favorable.
change from baseline to 4 months
Body composition
Tidsramme: change from baseline to 8 months

Ratio of percent lean mass to percent adiposity as measured by DEXA. More lean mass and less adiposity is favorable.
change from baseline to 8 months

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Serum Biomarker Inflammation - C-Reactive Protein
Tidsramme: Change from baseline to 4 month

Analyzed by EVE technologies using standard ELISA kits
Change from baseline to 4 month
Serum Biomarker Insulin Resistance - Insulin
Tidsramme: Change from baseline to 4 month

Analyzed by EVE technologies using standard ELISA kits
Change from baseline to 4 month
Serum Biomarker Insulin Resistance- Glucose
Tidsramme: Change from baseline to 4 month

Analyzed by EVE technologies using standard ELISA kits
Change from baseline to 4 month
Serum Biomarker Inflammation - Tumor Necrosis Factor - alpha
Tidsramme: Change from baseline to 4 month

Analyzed by EVE technologies using standard ELISA kits
Change from baseline to 4 month
Serum Biomarker Insulin Resistance- C-Peptide
Tidsramme: Change from baseline to 4 month

Analyzed by EVE technologies using standard ELISA kits
Change from baseline to 4 month
Serum Biomarker Adipokine Dysregulation - Adiponectin
Tidsramme: Change from baseline to 4 month

Analyzed by EVE technologies using standard ELISA kits
Change from baseline to 4 month
Serum Biomarker Adipokine Dysregulation - Leptin
Tidsramme: Change from baseline to 4 month

Analyzed by EVE technologies using standard ELISA kits
Change from baseline to 4 month
Serum Biomarker Inflammation - Interleukin 6
Tidsramme: Change from baseline to 4 month

Analyzed by EVE technologies using standard ELISA kits
Change from baseline to 4 month

Andre resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
nRNA and Metabolomics - exploratory
Tidsramme: Baseline to 3 months

MTo explore if microRNA (miRNA) signatures associated with inflammation and/or Metabolomics are altered with the EDC intervention. analyzed using a Seahorse Bioscience extracellular flux analyzer.
Baseline to 3 months

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Medical College of Wisconsin

Samarbejdspartnere

Loyola University Chicago

Efterforskere

  • Ledende efterforsker: Melinda Stolley, PhD, Principal Investigator

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

1. november 2022

Primær færdiggørelse (Faktiske)

30. juni 2026

Studieafslutning (Faktiske)

30. juni 2026

Datoer for studieregistrering

Først indsendt

19. februar 2018

Først indsendt, der opfyldte QC-kriterier

28. januar 2019

Først opslået (Faktiske)

31. januar 2019

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

6. oktober 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

2. oktober 2026

Sidst verificeret

1. april 2025

Mere information

Begreber relateret til denne undersøgelse

Yderligere relevante MeSH-vilkår

Andre undersøgelses-id-numre

  • 27600

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner